When the pharmaceutical directory is not sufficient

Extemporaneous medicines are tailored to the needs of patients who cannot be treated with medications available on the market. There are many reasons why this may be the case: the right substance, strength or formulation is lacking, or an approved medicine contains a substance or an excipient that causes a patient’s adverse reaction. Individually adapted medications complement approved treatments and fill an important gap when medicines become deregistered.

Our task is to develop and manufacture individually adapted medicines for patients with additional needs. The option of receiving individually adapted medicines is of great value to many patients. Often, their quality of life is significantly enhanced. Sometimes, access to extemporaneous medicines may be the difference between life and death. There are many conditions where extemporaneous medications may be the solution, and we describe some of them below.

APL is a key supplier to healthcare professionals, pharmacies and patients with additional needs, offering a steady supply of quality-assured and individually adapted medicines.

Congenital chloride diarrhea

Few children in Sweden suffer from congenital chloride diarrhea, a psycho-socially challenging condition. There is no approved treatment, but the raw material, sodium butyrate, has proved effective. We have investigated the raw material source and produced a suitable composition in close collaboration with healthcare professionals. Now, patients can receive sodium butyrate in 250 mg capsules.


Tuberculosis is one of the most common infectious diseases worldwide. Over 9 million people contract it every year, and around 2 million of them die. The disease commonly affects young adults, as well as children and seniors. In the last decade, the number of cases in Sweden has increased by as much as 50%, in particular among the foreign-born population. APL’s oral solution isoniazid is used with the antibiotic rifampicin to treat tuberculosis in children.

Cancer pain

Many end-of-life-care cancer patients are cared for in a home environment. As pain relief constitutes a significant part of the treatment at this stage, it is important to adapt it according to the patient’s individual needs. Often, there is a demand for several pain relief medicines with varying effects. There are approved medicines for this purpose, but they do not always come in the combinations, strengths or formulations required by the patients. For this reason, we manufacture treatments using the most suitable substances and strengths. One example is morphine 10 mg/ml infusion solution in a Deltec cassette, which the patient can carry around for continuous pain relief and increased freedom.

Osler's desease

As of 2017, around 5,000 people in Sweden have been diagnosed with Osler’s disease. Symptoms include nosebleeds and anemia, caused by the expansion of small blood vessels that burst. Bevacizumab, a monoclonal antibody for local treatment in the nose, has been requested by healthcare professionals. Currently, it is only approved as an infusion used in cancer treatment. Based on existing scientific documentation and our experience, we have re-formulated the approved medication into a nose spray.

Infected eczema

Serious eczema risks becoming infected, usually by Staphylococcus or Streptococcus bacteria. There was an approved treatment containing neomycin, but it was deregistered in 2008. As there is still a clinical need, we began manufacturing a cream that includes betamethasone-neomycin – something that both patients and dermatologists appreciate.

handfull röda kapslar

Our task

We are a key supplier to healthcare, pharmacies and patients with additional needs of a stable supply of quality-assured and individually adapted medicines. For healthcare as a whole, APL contributes clearly to continuity, patient safety and cost effectiveness.

We contributes to continuity and cost-effectiveness of healthcare while keeping patients safe.

Read more about our role in the society



Extemporeläkemedel och lagerberedningar

Beställ online via EbEx


Telefon: 010-447 97 00
e-post: kundservice@apl.se


Ordinarie öppettider:
Helgfria vardagar 08:00-17:00.


Öppettider sommar:
Helgfria vardagar 08:00-16:00.

Gäller 24 juni-16 augusti 2024.



Reservrutinen används endast för akuta medicinskt viktiga beställningar av extemporeläkemedel under tiden EbEx ordersystem inte kan nås. För att kunna använda dig av rutinen så krävs det att du redan är befintlig kund hos APL och har ett kundnummer.

Beställningar görs på för ändamålet avsedd blankett och får inte innehålla några patientuppgifter.

Beställningen skickas via e-post till kundservice@apl.se.



Visiting adress:

Prismavägen 2, Kungens Kurva

+46 10 447 96 00

Other contact information

About APL

Apotek Produktion & Laboratorier (APL) is one of Europe’s leading companies manufacturing extemporaneous drugs and stock preparations. We have a public policy assignment from the Swedish government, but also work together with other pharmaceutical companies to create the greatest possible patient benefit. The assignment also comprises preparedness to maintain operations in times of crisis and ultimately war.

Our vision is that we will make a difference for patients with additional needs. We are also an established contract manufacturer within life science in Scandinavia, where we deliver services within development and analysis. With more than 500 employees and five manufacturing units in Malmö, Gothenburg, Stockholm and Umeå, we develop drugs that improve and save lives.

Read more